 |
 |
 |
 |
 |
 |
 |
 |
Expert
Reviews in Molecular Medicine: http://www.expertreviews.org/
DOI: 10.1017/S146239940800077X; 1 August 2008
Martin
Köbel, David Huntsman and C. Blake Gilks (2008) Critical molecular abnormalities
in high-grade serous carcinoma of the ovary. Expert Rev. Mol. Med. Vol. 10,
e22, DOI: 10.1017/S146239940800077X
Critical molecular abnormalities in high-grade serous carcinoma of the ovary
Martin Köbel a1
a2, David Huntsman a1 and C. Blake Gilks a1 c1
a1 Genetic Pathology Evaluation Centre of the Prostate Research Centre, Department of Pathology, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver BC, Canada.
a2 Institute of Pathology, Charité Hospital, Berlin 10117, Germany.
c1 Corresponding author: C. Blake Gilks, Department of Pathology, Room 1207 1st floor JPPN, Vancouver General Hospital, 855 West 12th Ave, Vancouver, BC, Canada, V5Z 1M9. Tel: +1 (604) 875 4901; Fax: +1 (604) 875 4797; E-mail: Blake.Gilks@vch.ca
Ovarian carcinomas show more morphological heterogeneity than adenocarcinomas of any other body site. It has recently become clear that the morphologically defined subtypes of ovarian carcinoma are distinct diseases, with different risk factors, molecular events during oncogenesis, likelihood of spread, responses to chemotherapy, and outcomes. This review focuses on molecular abnormalities (in genes expressing BRCA1/2, TP53 and RB1/CCND1/CDKN2A/E2F) found in high-grade serous carcinomas of the ovary, which account for most ovarian cancer deaths. These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice.
Full
text online (purchase or subscribe through
Cambridge Journals Online)
| home
| search | glossary
| links | sitemap
| contact |
Expert Reviews in Molecular Medicine © Cambridge
University Press ISSN 1462-3994 (Disclaimer and copyright)
Editorial Office: Centre for Applied Research
in Educational Technologies (CARET), 1st Floor, 16 Mill Lane, Cambridge,
CB2 1SB, UK. Tel: +44 (0)1223 765 375; Fax: +44(0)1223 765 505; E-mail: ermm@caret.cam.ac.uk